Harel Insurance Investments & Financial Services Ltd. Sells 150 Shares of Danaher Co. (NYSE:DHR)

Harel Insurance Investments & Financial Services Ltd. decreased its holdings in Danaher Co. (NYSE:DHR) by 31.8% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 321 shares of the conglomerate’s stock after selling 150 shares during the period. Harel Insurance Investments & Financial Services Ltd.’s holdings in Danaher were worth $74,000 at the end of the most recent reporting period.

Other hedge funds have also recently made changes to their positions in the company. DHJJ Financial Advisors Ltd. bought a new position in shares of Danaher in the third quarter worth about $25,000. BKM Wealth Management LLC bought a new position in shares of Danaher in the fourth quarter worth about $27,000. OFI Invest Asset Management bought a new position in shares of Danaher in the third quarter worth about $30,000. First Capital Advisors Group LLC. bought a new position in shares of Danaher in the second quarter worth about $32,000. Finally, BOK Financial Private Wealth Inc. bought a new position in shares of Danaher in the third quarter worth about $34,000. Institutional investors own 79.05% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on DHR shares. StockNews.com cut Danaher from a “buy” rating to a “hold” rating in a report on Wednesday, January 31st. Barclays raised their price target on Danaher from $240.00 to $260.00 and gave the company an “equal weight” rating in a report on Wednesday, April 10th. Royal Bank of Canada raised their price target on Danaher from $254.00 to $282.00 and gave the company an “outperform” rating in a report on Wednesday, January 31st. Citigroup raised their price target on Danaher from $255.00 to $280.00 and gave the company a “buy” rating in a report on Wednesday, January 31st. Finally, Raymond James lifted their target price on Danaher from $240.00 to $270.00 and gave the stock an “outperform” rating in a report on Wednesday, January 31st. Seven research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $267.43.

Danaher Price Performance

Shares of DHR stock opened at $240.35 on Wednesday. Danaher Co. has a 52-week low of $182.09 and a 52-week high of $259.00. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.37 and a current ratio of 1.68. The firm has a market capitalization of $177.99 billion, a P/E ratio of 37.61, a P/E/G ratio of 3.65 and a beta of 0.83. The stock has a 50 day moving average price of $249.42 and a 200 day moving average price of $229.79.

Danaher (NYSE:DHR) last issued its quarterly earnings results on Tuesday, January 30th. The conglomerate reported $2.09 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.91 by $0.18. Danaher had a return on equity of 12.25% and a net margin of 17.26%. The firm had revenue of $6.41 billion during the quarter, compared to analyst estimates of $6.10 billion. During the same period last year, the company earned $2.87 EPS. Danaher’s quarterly revenue was down 10.2% compared to the same quarter last year. As a group, sell-side analysts predict that Danaher Co. will post 7.62 earnings per share for the current year.

Danaher Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, April 26th. Shareholders of record on Thursday, March 28th will be given a dividend of $0.27 per share. The ex-dividend date of this dividend is Wednesday, March 27th. This is a positive change from Danaher’s previous quarterly dividend of $0.24. This represents a $1.08 dividend on an annualized basis and a yield of 0.45%. Danaher’s payout ratio is 16.90%.

Insider Buying and Selling at Danaher

In other Danaher news, Director Teri List sold 3,289 shares of Danaher stock in a transaction on Tuesday, February 6th. The stock was sold at an average price of $248.32, for a total transaction of $816,724.48. Following the completion of the sale, the director now directly owns 19,726 shares of the company’s stock, valued at approximately $4,898,360.32. The sale was disclosed in a filing with the SEC, which is available at the SEC website. In other news, SVP Daniel Raskas sold 23,757 shares of the business’s stock in a transaction on Monday, February 26th. The stock was sold at an average price of $252.00, for a total value of $5,986,764.00. Following the completion of the transaction, the senior vice president now directly owns 38,102 shares of the company’s stock, valued at approximately $9,601,704. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Teri List sold 3,289 shares of the business’s stock in a transaction on Tuesday, February 6th. The stock was sold at an average price of $248.32, for a total value of $816,724.48. Following the completion of the transaction, the director now directly owns 19,726 shares of the company’s stock, valued at $4,898,360.32. The disclosure for this sale can be found here. Insiders sold a total of 32,957 shares of company stock valued at $8,265,802 in the last ninety days. Corporate insiders own 10.90% of the company’s stock.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.